IMMUNITYBIO INC (IBRX) Stock Analyst Earnings Estimates
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 930K 52.46% | 240K -74.19% | 622K 159.17% | 15.3M 2,359.81% | 138.94M 808.10% | 337.4M 142.84% | 860.05M 154.91% | 1.819B 111.50% | 4.189B 130.29% | 7.133B 70.28% | 12.297B 72.40% | 16.686B 35.69% | |
| EBITDA YoY % growth | -316.04M -60.04% | -332.36M -5.16% | -342.852M -3.16% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -330.28M -57.11% | -350.62M -6.16% | -361.364M -3.06% | -367.7M -1.75% | -301.267M 18.07% | -103.552M 65.63% | 469.45M 553.35% | 1.189B 153.28% | 3.382B 184.44% | 6.051B 78.92% | 10.705B 76.91% | 14.653B 36.88% | |
| Operating Margin | -35,513.98% | -146,091.67% | -58,097.11% | -2,403.27% | -216.83% | -30.69% | 54.58% | 65.37% | 80.74% | 84.83% | 87.05% | 87.82% | |
| EPS YoY % growth | -0.89 0.00% | -1.05 -17.98% | -1.13 -7.62% | -0.82 27.79% | -0.68 16.25% | -0.33 51.74% | 0.72 319.59% | 2.35 223.94% | 4.77 103.48% | 8.42 76.28% | 14.60 73.45% | 18.78 28.65% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 41.71% | -0.16 18.40% | -0.16 20.95% | -0.15 -27.50% | -0.15 25.00% |
| Revenue Q2Q % growth | 7.973M 5,635.97% | 23.521M 58,702.50% | 31.171M 2,877.17% | 37.546M 514.90% | 42.636M 434.75% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -91.931M -8.79% | -80.832M 15.09% | -77.507M 21.97% | -75.438M 6.00% | -71.109M 22.65% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.12 36.84% | -0.18 | 0.06 | 34.64% |
| Q2 2024 Q2Q % growth | -0.20 37.50% | -0.17 | -0.03 | -15.34% |
| Q1 2024 Q2Q % growth | -0.20 25.93% | -0.16 | -0.04 | -22.55% |
| Q4 2023 Q2Q % growth | -0.35 -29.63% | -0.18 | -0.17 | -90.63% |
| Q3 2023 Q2Q % growth | -0.19 32.14% | -0.26 | 0.07 | 26.95% |
| Q2 2023 Q2Q % growth | -0.32 -33.33% | -0.24 | -0.08 | -33.50% |
| Q1 2023 Q2Q % growth | -0.27 -3.85% | -0.28 | 0.01 | 1.96% |
| Q4 2022 Q2Q % growth | -0.27 -17.39% | -0.22 | -0.05 | -20.32% |
| Q3 2022 Q2Q % growth | -0.28 -27.27% | -0.23 | -0.05 | -19.35% |
| Q2 2022 Q2Q % growth | -0.24 -4.35% | -0.24 | 0.00 | 1.96% |
| Q1 2022 Q2Q % growth | -0.26 -23.81% | -0.22 | -0.04 | -15.86% |
| Q4 2021 Q2Q % growth | -0.23 23.33% | -0.21 | -0.02 | -7.38% |
| Q3 2021 Q2Q % growth | -0.22 -10.00% | -0.20 | -0.02 | -7.84% |
| Q2 2021 Q2Q % growth | -0.23 -15.00% | -0.12 | -0.11 | -87.91% |
| Q1 2021 Q2Q % growth | -0.21 -10.53% | -0.42 | 0.21 | 49.78% |
| Q4 2020 Q2Q % growth | -0.30 -87.50% | -0.18 | -0.12 | -63.40% |
| Q3 2020 Q2Q % growth | -0.20 -25.00% | -0.18 | -0.02 | -8.93% |
| Q2 2020 Q2Q % growth | -0.20 -17.65% | -0.19 | -0.01 | -3.20% |
| Q1 2020 Q2Q % growth | -0.19 13.64% | -0.17 | -0.02 | -9.57% |
| Q4 2019 Q2Q % growth | -0.16 | -0.20 | 0.04 | 21.57% |
| Q3 2019 Q2Q % growth | -0.16 | -0.19 | 0.03 | 13.81% |
| Q2 2019 Q2Q % growth | -0.17 | -0.25 | 0.08 | 30.70% |
| Q1 2019 Q2Q % growth | -0.22 | -0.24 | 0.02 | 8.22% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 6.106M 7,346.34% | 2.985M | 3.121M | 104.56% |
| Q2 2024 Q2Q % growth | 1.047M 2,453.66% | 2.57M | -1.523M | -59.26% |
| Q1 2024 Q2Q % growth | 40K -88.89% | 25.5K | 14.5K | 56.86% |
| Q4 2023 Q2Q % growth | 139K 98.57% | 25.5K | 113.5K | 445.10% |
| Q3 2023 Q2Q % growth | 82K -31.67% | 25.5K | 56.5K | 221.57% |
| Q2 2023 Q2Q % growth | 41K 2.50% | 25.5K | 15.5K | 60.78% |
| Q1 2023 Q2Q % growth | 360K 3,500.00% | 25.5K | 334.5K | 1,311.76% |
| Q4 2022 Q2Q % growth | 70K -82.05% | 25.5K | 44.5K | 174.51% |
| Q3 2022 Q2Q % growth | 120K 71.43% | 25.5K | 94.5K | 370.59% |
| Q2 2022 Q2Q % growth | 40K -88.24% | 25.5K | 14.5K | 56.86% |
| Q1 2022 Q2Q % growth | 10K -92.86% | 25.5K | -15.5K | -60.78% |
| Q4 2021 Q2Q % growth | 390K 360.00% | 25.5K | 364.5K | 1,429.41% |
| Q3 2021 Q2Q % growth | 70K -53.33% | 25.5K | 44.5K | 174.51% |
| Q2 2021 Q2Q % growth | 340K -22.73% | 25.5K | 314.5K | 1,233.33% |
| Q1 2021 Q2Q % growth | 140K -17.65% | 25.5K | 114.5K | 449.02% |
| Q4 2020 Q2Q % growth | -150K -106.91% | 15.3K | -165.3K | -1,080.39% |
| Q3 2020 Q2Q % growth | 150K 1,400.00% | 7.65K | 142.35K | 1,860.78% |
| Q2 2020 Q2Q % growth | 440K 2,100.00% | 7.65K | 432.35K | 5,651.63% |
| Q1 2020 Q2Q % growth | 170K 1,600.00% | 170K | % | |
| Q1 2019 Q2Q % growth | 10K | 3.57K | 6.43K | 180.11% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -17.65% | -33.33% | 4% | 2.44% |
| Revenue | -13.63% | -65.63% | -5.96% | 47.9% |